Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Collaboration to Focus on Women’s Health Diagnostic Solutions

By LabMedica International staff writers
Posted on 18 Jun 2013
Two companies have entered into a collaboration that will feature the national availability of a cervical cancer-screening test in addition to developing and expanding access to diagnostic solutions for women’s health.

Quest Diagnostics (Madison, N.J. More...
USA), a global diagnostic information services company, and Hologic, Inc. (Bedford, MA, USA), a developer, manufacturer, and supplier of diagnostics products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women, have entered into a strategic alliance to more broadly offer testing based on Hologic’s Aptima range of products, as well as to codevelop and promote advanced diagnostic solutions to improve women's health.

Under the nonexclusive agreement, which has an initial term of five years, the companies will focus primarily on clinical areas critical to the health of women. Quest Diagnostics will develop a broader offering of services based on Hologic’s Aptima family of products, which includes US Food and Drug Administration (FDA; Silver Spring, MD, USA)-approved or cleared assays for human papillomavirus (HPV), HPV genotyping, Chlamydia, gonorrhea, and Trichomonas vaginalis. In addition, Quest Diagnostics will continue to utilize Hologic's leading line of ThinPrep liquid-based cytology products.

Quest Diagnostics will also continue to offer Hologic’s Aptima HPV mRNA-based assay nationally. The Aptima HPV assay detects messenger RNA overexpressed from two viral oncogenes that are integral to the development of cervical cancer. Hologic’s Aptima HPV assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens.

The companies will also explore opportunities to develop and expand access to new diagnostic solutions for women’s health. In addition, they will implement joint programs to advance women’s health issues with medical associations and patient advocacy groups and to sponsor research. Financial terms of the collaboration were not disclosed.

“Our relationship with Hologic also demonstrates our progress executing on our restore growth and operational excellence strategies,” said Mr. Rusckowski, Quest’s CEO. “With this alliance, we will strengthen the specialization and competitiveness of our women's health business. We are also working more closely and strategically with suppliers, and this alliance is the first under our new, highly rigorous supplier engagement model, which we unveiled at our first ever Supplier Forum in March.”

Related Links:

Quest Diagnostics
Hologic
US Food and Drug Administration



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.